Cost-Effectiveness of the Angiotensin Receptor Neprilysin Inhibitor Sacubitril/Valsartan for Patients with Chronic Heart Failure and Reduced Ejection Fraction in the Netherlands: A Country Adaptation Analysis Under the Former and Current Dutch Pharmacoeconomic Guidelines
Autor: | Joan G. Meeder, Matthijs Versteegh, Maureen P.M.H. Rutten-van Mölken, Rudolf A. de Boer, Gerard C.M. Linssen, Jolanda M.A. Koenders, Isaac Corro Ramos |
---|---|
Přispěvatelé: | Cardiovascular Centre (CVC), Health Technology Assessment (HTA) |
Jazyk: | angličtina |
Rok vydání: | 2017 |
Předmět: |
Male
Cost effectiveness Cost-Benefit Analysis productivity costs Tetrazoles heart failure Angiotensin-Converting Enzyme Inhibitors Expected value of perfect information UNCERTAINTY 030204 cardiovascular system & hematology DECISION-MAKING ECONOMIC-EVALUATION 0302 clinical medicine Netherlands Randomized Controlled Trials as Topic education.field_of_study Aminobutyrates 030503 health policy & services Health Policy cost-effectiveness analysis Cost-effectiveness analysis EFFECTIVENESS MODELS Middle Aged Drug Combinations Models Economic HEALTH-CARE TECHNOLOGIES ENALAPRIL Valsartan Female Neprilysin Quality-Adjusted Life Years 0305 other medical science medicine.drug medicine.medical_specialty Population Guidelines as Topic Angiotensin Receptor Antagonists 03 medical and health sciences ASSOCIATION CLASSES ACE inhibitor medicine Humans SENSITIVITY ANALYSIS Economics Pharmaceutical Enalapril Intensive care medicine education Aged business.industry MORTALITY Biphenyl Compounds Public Health Environmental and Occupational Health Stroke Volume Chronic Disease Economic evaluation INFORMATION ANALYSIS business Sacubitril Valsartan |
Zdroj: | Value in Health, 20(10), 1260-1269. ELSEVIER SCIENCE INC Value in Health. Elsevier Ltd. |
ISSN: | 1098-3015 |
Popis: | Objectives: To describe the adaptation of a global health economic model to determine whether treatment with the angiotensin receptor neprilysin inhibitor LCZ696 is cost effective compared with the angiotensin-converting enzyme inhibitor enalapril in adult patients with chronic heart failure with reduced left ventricular ejection fraction in the Netherlands; and to explore the effect of performing the cost-effectiveness analyses according to the new pharmacoeconomic Dutch guidelines (updated during the submission process of LCZ696), which require a value-of-information analysis and the inclusion of indirect medical costs of life-years gained.Methods: We adapted a UK model to reflect the societal perspective in the Netherlands by including travel expenses, productivity loss, informal care costs, and indirect medical costs during the life-years gained and performed a preliminary value-of-information analysis.Results: The incremental cost-effectiveness ratio obtained was (sic)17,600 per quality-adjusted life-year (QALY) gained. This was robust to changes in most structural assumptions and across different subgroups of patients. Probability sensitivity analysis results showed that the probability that LCZ696 is cost-effective at a (sic)50,000 per QALY threshold is 99.8%, with a population expected value of perfect information of (sic)297,128. On including indirect medical costs of life-years gained, the incremental cost-effectiveness ratio was (sic)26,491 per QALY gained, and LCZ696 was 99.46% cost effective at (sic)50,000 per QALY, with a population expected value of perfect information of (sic)2,849,647.Conclusions: LCZ696 is cost effective compared with enalapril under the former and current Dutch guidelines. However, the (monetary) consequences of making a wrong decision were considerably different in both scenarios. Copyright (C) 2017, International Society for Pharmacoeconomics and Outcomes Research (ISPOR). Published by Elsevier Inc. |
Databáze: | OpenAIRE |
Externí odkaz: |